Skip to content

Risk factors and treatment strategies for progression of non proliferative diabetic retinopathy complicated with diabetic nephropathy

Risk factors and treatment strategies for progression of non proliferative diabetic retinopathy complicated with diabetic nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125624
Enrollment
Unknown
Registered
2026-05-28
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combining non-proliferative diabetic retinopathy in diabetic nephropathy

Interventions

Non-proliferative diabetic retinopathy (mild to moderate):None
Non-proliferative diabetic retinopathy (severe) complicated with diabetic nephropathy:None
Non-proliferative diabetic retinopathy (mild to moderate) complicated with diabetic nephropathy:None
Non-proliferative diabetic retinopathy (severe):None

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Include patients with non-proliferative diabetic retinopathy (NPDR) in the study.

Exclusion criteria

Exclusion criteria: 1.Patients who have previously received intravitreal drug injections, retinal photocoagulation, or intraocular surgery; 2.Individuals with other retinal conditions such as retinal vein occlusion, retinal aneurysm disease, age-related macular degeneration, macular pre-macular membrane, or macular hole; 3.Combine other eye diseases such as glaucoma, pathological myopia, optic neuritis, eye trauma, amblyopia, etc; 4.Patients with severe cardiovascular and cerebrovascular diseases, severe liver and kidney dysfunction, and those with a history of drug allergies who cannot tolerate the examination and treatment should be combined; 5.Images of unclear ocular media cannot be collected clearly.

Design outcomes

Primary

MeasureTime frame
Clinical Progression of Diabetic Retinopathy Stage 1;

Secondary

MeasureTime frame
Best-corrected visual acuity (logMAR) decreased by 3 lines or more;

Countries

China

Contacts

Public ContactYan Yujie

China-Japan Friendship Hospital

185007736@qq.com+86 10 84205357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026